EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Please see below for Important Safety Information for EPCLUSA.
Formulary information is provided by Fingertip Formulary® and is current as of 7/22/2020. Because formularies do change and many health plans offer more than one formulary, please check with the health plan directly to confirm coverage for individual patients.
Click here for patient
support information, which
may assist in identifying coverage
options for your patients.
The references to company/plan names listed do not, in any manner, imply an endorsement of EPCLUSA or any other
products by the referenced companies/plans.
Placement on the formulary is not intended to imply any claims regarding safety or efficacy of the products
referenced.
Help patients register for a co-pay coupon. Commercial patients may pay as little as $15 for a full course of EPCLUSA
Visit the EPCLUSA patient website to learn more
Check Your Patients' EligibilityCommercial patients may pay as little as $5 per co-pay for their medicine. Patients are not eligible if they are enrolled in a government healthcare prescription drug program such as Medicare Part D or Medicaid (including patients who are in the Medicare coverage gap known as the “donut hole”).
The EPCLUSA Co-pay Coupon Program will cover the out-of-pocket costs for EPCLUSA prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen of EPCLUSA.
Commercial patients may pay as little as $5 per co-pay for their medicine. Patients are not eligible if they are enrolled in a government healthcare prescription drug program such as Medicare Part D or Medicaid (including patients who are in the Medicare coverage gap known as the “donut hole”).
The EPCLUSA Co-pay Coupon Program will cover the out-of-pocket costs for EPCLUSA prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen of EPCLUSA.
Talk with Support Path:
1-855-7-MYPATH (1-855-769-7284)
Visit MySupportPath.comBOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.
Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.
BOXED WARNING: RISK OF HEPATITIS B : REACTIVATIONTest all patients for evidence of current or prior hepatitis B virus (HBV)...
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
References: